Global Recombinant Human Endostatin Market Growth 2025-2031

Global Recombinant Human Endostatin Market Growth 2025-2031

The global Recombinant Human Endostatin market size is predicted to grow from US$ 157 million in 2025 to US$ 254 million in 2031; it is expected to grow at a CAGR of 8.3% from 2025 to 2031.

Endostatin is a naturally occurring, 20-kDa C-terminal fragment derived from type XVIII collagen. Human monomeric endostatin is a globular protein containing two disulfide bonds: Cys162−302 and Cys264−294.

The market for recombinant human endostatin is important in cancer treatment. Trends include research into combination therapies and targeted cancer treatments.

LP Information, Inc. (LPI) ' newest research report, the “Recombinant Human Endostatin Industry Forecast” looks at past sales and reviews total world Recombinant Human Endostatin sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human Endostatin sales for 2025 through 2031. With Recombinant Human Endostatin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Endostatin industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Human Endostatin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Endostatin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human Endostatin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Endostatin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Endostatin.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Endostatin market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Purity:95%
Others

Segmentation by Application:
Medical Care
Scientific Research
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
PeproTech

Key Questions Addressed in this Report

What is the 10-year outlook for the global Recombinant Human Endostatin market?

What factors are driving Recombinant Human Endostatin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Recombinant Human Endostatin market opportunities vary by end market size?

How does Recombinant Human Endostatin break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.